Navigation Links
Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
Date:10/21/2010

RICHMOND, Calif., Oct. 21 /PRNewswire/ -- Lumiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation technology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announced that they have signed a global agreement on incorporation of Lumiphore's Lumi4® complexes in Algeta's targeted radiotherapeutics and companion diagnostics.

Under the agreement, Algeta has an option to the exclusive rights to incorporate Lumi4® isophthalamide chelation technology into future targeted radiopharmaceutical therapeutics for cancer.

"Lumiphore's goal is to bring the benefits of bifunctional metal-chelation technology to therapeutic markets that use targeted radiopharmaceuticals to treat cancer. The ability to chelate radioactive metal isotopes and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond, President and CEO of Lumiphore.

Algeta has proprietary technology relating to the use of the alpha emitter thorium-227 to protein/peptides to target specific cancer cells. Thorium-227 is an isotope that emits high-energy alpha particles. Such isotopes are of considerable interest in the treatment of cancer as they are potent at killing tumor cells but have a highly localized effect. By linking thorium-227 to tumor-targeting molecules such as monoclonal antibodies, Algeta has the potential to create a pipeline of new generation alpha-pharmaceuticals designed to specifically seek and destroy cancers while minimizing damage to surrounding healthy tissues. "Using Lumi4® bifunctional chelates," explained Thomas Ramdahl, Chief Technology Officer of Algeta, "could create a new class of radioimmunotherapeutics. By linking thorium-227 to selected tumor targeting an
'/>"/>

SOURCE Lumiphore, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
2. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
3. Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents
4. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
5. Hanger Orthopedic Group, Inc. Announces Pricing of $200 Million of Senior Notes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
7. K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment
8. Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010
9. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
10. Amgen Announces Webcast of 2010 Third Quarter Financial Results
11. ERT to Announce Third Quarter 2010 Results on November 4, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Reaching a critical milestone in the ... of Boards of Pharmacy ® (NABP ® ) ... has passed the Internet Corporation for Assigned Names and ... .PHARMACY gTLD by the end of 2013, and will ... and related entities that are located in ...
(Date:5/21/2013)... 21, 2013 Valeant Pharmaceuticals ... ) (TSX: VRX) today announced the ... its 2013 annual meeting of shareholders ... vote for the election of directors ... Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. ...
(Date:5/21/2013)... de 2013 La junta directiva de ... OMNIlife science®, Inc., Enztec, Ltd. y Praxim, SA, han ... Mayer, un ejecutivo ortopédico experimentado, será vicepresidente de ... , un experto refutado en dispositivos médicos, ... unirse a OSI como presidente de la junta, ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3
... DIEGO, Sept. 8 ResMed Inc. (NYSE: RMD ... company,s outstanding shares of common stock, payable in the form ... 2010. The new total shares outstanding doubled to 151,388,240 shares, ... the company,s common stock on the New York Stock Exchange ...
... 8 Transgenomic, Inc. (OTC Bulletin Board: ... chief executive officer, will deliver the Company,s corporate presentation ... Conference on Monday, September 13 at 4:55 p.m. EDT. ... in New York City from September 13th – 15th, ...
Cached Medicine Technology:Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 2Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 3
(Date:5/21/2013)... 21, 2013 Patients of Dr. Michael Shenk ... lost teeth due to gum disease and would like permanent ... disease treatment with laser gum surgery. Gum disease ... highest success rate out of all tooth replacement options. ... relatively new procedure cleared by the Food and Drug Administration ...
(Date:5/21/2013)... ContinuCare Home Health, Inc. recently received a ... Disability Services. After completing a four-day review of patient ... Health was found to have no deficiencies to be ... Department of Aging and Disability Services’ mission to provide ... and opportunities that are easily accessed in local ...
(Date:5/21/2013)... SOURCE XT one of the largest, post-approval transcatheter ... at EuroPCR 2013 show good clinical outcomes in routine ... all access approaches, valve sizes and delivery systems. , ... enrolled patients (mean age 81.5 years) undergoing TAVI with ... 17 countries between July 2010 and October 2011. Access ...
(Date:5/21/2013)... The In View series , a ... channels across the country, announces it has posted a ... producers of the series proudly bring audiences across the ... manufacturing industry, health-related companies, medical facilities and more. The ... in all parts of the United States, Canada and ...
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... relationships. With the help of Texas Counseling’s Sexuality ... of communication, and the development of healthier habits ... group workshops available for both couples and individuals ... couples enhance their relationships and learn skills to ...
Breaking Medicine News(10 mins):Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2
... Human Vaccine Institute today announced a collaboration and ... enable the rapid development of a vaccine and ... threat such as pandemic influenza. The team, composed ... of the National Institute of Allergy and Infectious ...
... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) -- While ... the past few decades, this tragic outcome is still a reality ... a series of studies published online April 14 in The ... in the United States may be obesity, which can raise the ...
... of minor illnesses of astronauts in space may require special ... the space environment. That,s according to Dr. Putcha and ... published online in The AAPS Journal suggest that ... shorter shelf-life than they do on Earth. Pharmaceuticals used ...
... The judgments we make about the intimacy of ... brain chemical serotonin, reports a new study published in ... of serotonin activity had been lowered, rated couples in ... volunteers with normal serotonin activity. The approach involved giving ...
... (HealthDay News) -- Home safety devices greatly reduce the ... a new study. Researchers at Cincinnati Children,s Hospital ... newborns. One set of families had properly installed and ... cabinet locks, electrical outlet covers, smoke alarms, carbon monoxide ...
... By Amanda Gardner HealthDay Reporter , ... highlight the complexities hospitals face in controlling and containing ... to many antibiotics. While one study showed that ... Staphylococcus aureus (MRSA), the other found no ...
Cached Medicine News:Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3Health News:Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies 2Health News:Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies 3Health News:Drug potency -- what happens in space? 2Health News:Serotonin: A critical chemical for human intimacy and romance 2Health News:With Safety Devices in Place, Kids' Injuries Decline: Study 2Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 2Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 3
5 mm concave jaws, cross action....
... inserter is the first of its kind. ... through a minimal incision. The special direct-acting ... bag with complete control and predictability. The ... easy around-the-clock, and the instrument has a ...
... SI-30 and SI-40 foldable lenses through incisions as ... clear corneal and corneal scleral tunnels. The inserter ... rounded blades for a secure grasp of a ... a .15 millimeter notch which may be used ...
KR-8000 Supra is capable of obtaining perfectly accurate keratometry and/or refraction measurements through pupils as narrow as 2.0 mm....
Medicine Products: